Trials / Conditions / Multidrug Resistant Tuberculosis

Multidrug Resistant Tuberculosis

21 registered clinical trials studyying Multidrug Resistant Tuberculosis — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) NCT07393438	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Recruiting	Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis ( NCT05534750	Assistance Publique - Hôpitaux de Paris	Phase 2
Recruiting	Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resi NCT05081401	Huashan Hospital	Phase 3
Unknown	Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial NCT05017324	Universiteit Antwerpen	N/A
Recruiting	Novel Triple-dose Tuberculosis Retreatment Regimen NCT04260477	Institute of Tropical Medicine, Belgium	Phase 3
Completed	Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS NCT04717908	Huashan Hospital	N/A
Unknown	MDR-TB Close Contacts Tracing in China (TCCT Study) NCT04484129	Huashan Hospital	—
Unknown	Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China NCT04421495	Beijing Chest Hospital	Phase 4
Completed	Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) NCT03867136	Huashan Hospital	Phase 4
Completed	Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial NCT03942354	Medecins Sans Frontieres, Netherlands	—
Unknown	NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB NCT03604848	Huashan Hospital	N/A
Completed	An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis NCT02454205	University of Cape Town	Phase 2 / Phase 3
Completed	Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment NCT02727582	University of Cape Town	—
Completed	Line Probe Assay Evaluation Study NCT02984579	Foundation for Innovative New Diagnostics, Switzerland	—
Unknown	Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide NCT02120638	Huashan Hospital	Phase 3
Unknown	Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan NCT02496572	Medecins Sans Frontieres, Netherlands	—
Completed	A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidr NCT01859923	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 2
Completed	Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resis NCT01856634	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 1
Completed	Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients NCT01521364	University Medical Center Groningen	Phase 4
Completed	Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis NCT01424670	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Linezolid to Treat Extensively-Drug Resistant Tuberculosis NCT00727844	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2